

CURRICULUM VITAE

Vito Di Lernia, MD

Responsabile Struttura Semplice di Dermatologia Immunologica e Pediatrica
Unità Operativa di Dermatologia
Arcispedale Santa Maria Nuova, Azienda USL-IRCCS di Reggio Emilia, Italia
Abilitazione Scientifica Nazionale alle funzioni di Professore di Seconda Fascia

Membro delle seguenti Associazioni Professionali

- SIDERP Italian Society of Pediatric Dermatology (Presidente)
- GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis
- IDS International Dermoscopy Society
- SIDeMaST Società Italiana di Dermatologia e Malattie a trasmissione sessuale (past Segretario-Coordiatore Gruppo di Dermatologia Pediatrica e Malattie rare)
- ADOI Italian Society of Hospital Dermatologists)
- Associazione Centro Studi GISED Gruppo Italiano per gli Studi Epidemiologici in Dermatology

Professional Training

1986 Laurea in Medicina e Chirurgia, Università degli Studi di Bologna
1989 Specializzazione in Dermatologia e Venereologia, Università di Bologna

Work Experience

1992-ongoing Unità Operativa di Dermatologia, Arcispedale Santa Maria Nuova,
Azienda USL-IRCCS di Reggio Emilia
2011-ongoing Responsabile di Struttura Semplice di Dermatologia Immunologica e
Pediatrica, Arcispedale Santa Maria Nuova, Azienda USL-IRCCS di Reggio Emilia

Attività accademica

Docente di Dermatologia, Facoltà di Odontoiatria, University di Padova, Anno Accademico
2017-18

Esperienza di ricerca in trial clinici

- CNTO1959PSO4013 - "Studio osservazionale su Guselkumab: efficacia e impatto sulla qualità della vita in pazienti affetti da psoriasi regionale (facciale e genitale) naïve o già trattati con farmaci biologici (Studio GULLIVER)." (Principal Investigator)
- Studio sugli esiti sanitari associati alla psoriasi (PSoHO): studio osservazionale internazionale degli esiti sanitari a 3 anni del trattamento biologico della psoriasi a placche da moderata a grave Codice protocollo I1F-MC-B007 (Principal Investigator)
- CNTO1979PSO3011 "A phase 3, Multicenter, Randomized, Placebo- and Active Comparator-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Subjects (<=6 to < 18 Years of Age) (Principal Investigator)
- A Phase 3, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Apremilast (CC-10004) in Pediatric Subjects from 6 Through 17 Years of Age with Moderate to Severe Plaque Psoriasis." (Principal Investigator)
- B7451015 EudraCT Number 2017-004851-22 "A Phase 3 Randomized, Double-blind, Multi-center, Long Term Extension Study Investigating the Efficacy and Safety of PF-04965842, with or without Topical Medications, Administered to Subjects Aged 12 Years and Older with Moderate to Severe Atopic Dermatitis" (Principal Investigator)
- "A phase 3 randomized withdrawal, double-blind, placebo-controlled, multi-center study investigating the efficacy and safety of PF-04965842 in subjects aged 12 years

and over, with moderate to severe atopic dermatitis with the option of rescue treatment in flaring subjects" (Principal Investigator).

- I4V-MC-JAIN (BREEZE-AD4) "A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Baricitinib in Combination with Topical Corticosteroids in Adult Patients with Moderate-to-Severe Atopic Dermatitis Who Have Experienced Failure to Cyclosporine or Are Intolerant to, or Have Contraindication to, Cyclosporine" (Principal Investigator)
- CHS-1420-02 – "A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-1420 Versus Humira® in Subjects With Chronic Plaque Psoriasis" (Principal Investigator)
- CAIN457AIT01-EudraCT: 2014-002865-31 "A 24-week, multicenter, prospective, open-label study to evaluate the efficacy in terms of non-inferiority with respect to PASI 90 response rate and the safety profile of secukinumab 300 mg in Cw6-negative and Cw6-positive patients with moderate to severe chronic plaque-type psoriasis (SUPREME)" (Co-Inv)
- CC-10004-BCT-002 "A phase 3, multicentre, randomized, double-blind, placebo-controlled parallel group study, followed by an active-treatment phase to evaluate the efficacy and safety of apremilast in the treatment of subjects with active Behcet's disease" (Co-Inv).
- CIGE025EIT01- "AWARE: A World-wide Antihistamine-Refractory chronic urticaria patient Evaluation" (Co-Inv)
- R668-AD-1416- EudraCT: 2014-002694-11 "A phase 3 confirmatory study investigating the efficacy and safety of dupilumab in monotherapy administered to adult patients with moderate to severe atopic dermatitis" (Principal Investigator)
- 2017- Studio osservazionale indipendente: "Adesione al registro nazionale dell'idrosadenite (IRHIS)"
- 2014-"Strategie di screening per pazienti psoriasici da candidare a valutazione reumatologica, finalizzate a diagnosticare l'Artrite Psoriasica"(Co-Inv)
- 2013- Studio osservazionale indipendente "L'acne e la donna adulta: studio osservazione sulle caratteristiche cliniche e sui fattori di rischio per gravità ed insorgenza" (Co-Inv)
- 2013 "Studio osservazionale indipendente: studio clinico-epidemiologico sul lichen sclerosus genitale" (Co-Inv)
- 2011 "Strategie a lungo termine di gestione clinica della psoriasi e studio controllato pragmatico sull'efficacia di interventi non farmacologici nel controllo della malattia. Farmacoeconomia e linee guida" (Co-Inv).
- COLO400CIT08 "Gender Attention" (Co-Inv)
- FARM5HS35J-2009 "Valutazione dell'effetto di esercizi di scrittura ed interventi di educazione sanitaria sulla qualità della vita dei pazienti con psoriasi" (Co-Inv)
- IT-09-20 "Progetto Daniele" (Co-Inv)
- IT-11-06 "Psodisk Validation Study. Validation of a new questionnaire for psoriasis patients"(Principal Investigator)
- 2009- FG-506-06-IT-01 "A long-term, non-comparative, multi-centre study to evaluate the efficacy and safety of 0.1% and 0.03% tacrolimus (FK506) ointment administered in adults with moderate to severe atopic dermatitis" (Co-Inv)

Articoli scientifici

134 articles published on indexed journals (PubMed)

H-index: 34 (Google Scholar); 24 (Scopus)

i-10 index (Google Scholar): 100

Attività editoriale

- Section Editor "Dermatology Practical & Conceptual"
- Consulting Editor for "Psoriasis Target & Therapy".

Attività di Referee:

- Ministère des solidarités et de la santé, Francia.
- Dutch Organisation for Health Research and Development, Olanda
- Archives of Dermatology
- Archives of Dermatological Research
- British Journal of Dermatology
- Clinical and Experimental Dermatology
- Dermatologic Therapy
- European Journal of Dermatology, Journal of Dermatology
- European Journal of Medical Genetics
- Giornale Italiano di Dermatologia e Venereologia
- Journal of Dermatology
- Journal of the European Academy of Dermatology and Venereology
- International Journal of Dermatology,
- American Journal of Clinical Dermatology
- Lupus
- Plos One

Publicazioni scientifiche ultimo quinquennio (2018-2022):

1. Costanzo A, Amerio P, Asero R, Chiricozzi A, Corazza M, Cristaudo A, Cusano F, Ferrucci SM, Nettis E, Patrizi A, Patrino C, Peris K, Picozza M, Stingeni L, Girolomoni G; Italian AD Study Group. Long-term management of moderate-to-severe adult atopic dermatitis: a consensus by the Italian Society of Dermatology and Venereology (SIDEMaST), the Association of Italian Territorial and Hospital Allergists and Immunologists (AAIITO), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA), and the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC). *Ital J Dermatol Venerol* 2021 Dec 21. Doi: 10.23736/S2784-8671.21.07129-2.
2. Arora P, Mrig S, Goldust Y, Kroumpouzou G, Karadağ AS, Rudnicka L, Galadari H, Szepietowski JC, Di Lernia V, Goren A, Kassir M, Goldust M. New Coronavirus (SARS-CoV-2) Crossing Borders Beyond Cities, Nations, and Continents: Impact of International Travel. *Balkan Med J.* 2021;38(4):205-211
PubMedID: 34274909 | DOI: 10.5152/balkanmedj.2021.21074 | IFg: 2,021
3. Viridi A, Patrizi A, Cambiaghi S, Diociaiuti A, El Hachem M, Schena D, Bassi A, Bonamonte D, Brazzelli V, Belloni Fortina A, Pepe P, Di Lernia V, Neri I. A retrospective study on clinical subtypes and management of morphea in 10 Italian Dermatological Units. *G Ital Dermatol Venereol.* ePub 2020 ott 16
PubMedID: 33070566 | DOI: 10.23736/S0392-0488.20.06632-8 | IFg: 2,011
4. Di Lernia Vito, Casanova Dahiana M, Simonetti Vito. Dupilumab may facilitate the clearance of molluscum contagiosum in atopic dermatitis patients. *J Dtsch Dermatol Ges.* 2020;18(9):1016-1018.ePub 2020 set 02
PubMedID: 32881369 | DOI: 10.1111/ddg.14257 | IFg: 5,584 |
5. Di Lernia V, Casanova DM, Ricci C. Apremilast in patients with history of malignancy: a real-life, single-center experience. *Int J Dermatol.* 2021;60(1):e22-e24.ePub 2020 ago 28
PubMedID: 32857434 | DOI: 10.1111/ijd.15093 | IFg: 2,736 |

6. Murrell Dedee F, Kroumpouzou George, Gupta Atula, di Lernia Vito, Sadoughifar Roxanna, Goldust Mohamad. Role of music therapy in reducing the burden of dermatological diseases during COVID-19. *Dermatol Ther.* 2020;33(6):e14086.ePub 2020 lug 28
PubMedID: 32720416 | DOI: 10.1111/dth.14086 | IFg: 2,851
7. Di Lernia V, Casanova DM, Ricci C. Brodalumab: another helpful option for HIV-positive psoriatic patients? *Dermatol Ther.* 2020;33(6):e13895.
PubMedID: 32584458 | DOI: 10.1111/dth.13895 | IFg: 2,851 |
8. Di Lernia Vito, Goldust Mohamad, Feliciani Claudio. Covid-19 infection in psoriasis patients treated with cyclosporin. *Dermatol Ther.* 2020;33(4):e13739.
PubMedID: 32478942 | DOI: 10.1111/dth.13739 | IFg: 2,851
9. Salvarani C, Bajocchi G, Mancuso P, Galli E, Muratore F, Boiardi L, Catanoso M, Pipitone N, Cassone G, Girolimetto N, Croci S, Cimino L, Gradellini F, Beltrami M, Di Lernia V, Dolci G, Massari M, Marata AM, Costantini M, Giorgi Rossi P. Susceptibility and severity of COVID-19 in patients treated with bDMARDs and tsDMARDs: a population-based study. *Ann Rheum Dis.* 2020;79(7):986-988.ePub 2020 mag 28
PubMedID: 32467245 | DOI: 10.1136/annrheumdis-2020-217903 | IFg: 19,103 | IRCCS 2020
10. Di Lernia Vito, Bombonato Caterina, Motolese Alberico. COVID-19 in an elderly patient treated with secukinumab. *Dermatol Ther.* 2020;33(4):e13580.ePub 2020 mag 27
PubMedID: 32406078 | DOI: 10.1111/dth.13580 | IFg: 2,851 | IRCCS 2020
11. Piccolo V, Neri I, Filippeschi C, Oranges T, Argenziano G, Battarra V C, Berti S, Manunza F, Fortina A B, Di Lernia V, Boccaletti V, De Bernardis G, Brunetti B, Mazzatenta C, Bassi A. Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients. *J Eur Acad Dermatol Venereol.* 2020;34(7):e291-e293.ePub 2020 mag 15
PubMedID: 32330334 | DOI: 10.1111/jdv.16526 | IFg: 6,166 | IRCCS 2020
12. Rudnicka L, Rokni Ghasem R, Lotti T, Wollina U, Fölster-Holst R, Katsambas A, Goren A, Di Lernia V, Rathod D, Mirabi A, Ghaffari A, Rajan A, Goldust M. Allergic contact dermatitis in patients with frontal fibrosing alopecia: An international multi-center study. *Dermatol Ther.* 2020;33(4):e13560.ePub 2020 mag 12
PubMedID: 32396259 | DOI: 10.1111/dth.13560 | IFg: 2,851
13. Goldust Mohamad, Weinberg Jeffrey M, Kircik Leon H, Sonthalia Sidharth, Di Lernia Vito, Rathod Dipali. Pityriasis Lichenoides Chronica in a Patient With Ankylosing Spondylitis Treated With Etanercept. *J Drugs Dermatol.* 2020;19(5):560-561
PubMedID: 32484616 | DOI: 10.36849/JDD.2020.2191 | IFg: 2,114 |
14. Di Lernia Vito. Reply: "Biologics for psoriasis during COVID-19 outbreak". *J Am Acad Dermatol.* 2020;82(6):e217-e218.ePub 2020 apr 10
PubMedID: 32283234 | DOI: 10.1016/j.jaad.2020.04.004 | IFg: 11,527
15. Bardazzi F, Bigi L, Campanati A, Conti A, Di Lernia V, Di Nuzzo S, Kaleci S, Lasagni C, Offidani AM, Giacchetti A, Nicolini M, Bettacchi A, Rosa L, Sacchelli L. Outcome following a short period of adalimumab dose escalation as rescue therapy in psoriatic patients. *Eur J Dermatol.* ePub 2020 apr 07
PubMedID: 32266875 | DOI: 10.1684/ejd.2020.3751 | IFg: 3,328

16. Di Lernia V. Antipsoriatic treatments during COVID-19 outbreak. *Dermatol Ther.* 2020;33(4):e13345.ePub 2020 mar 29
PubMedID: 32223073 | DOI: 10.1111/dth.13345 | IFg: 2,851 |
17. Filippi F, Odorici G, Conti A, Di Lernia V, Di Nuzzo S, Chessa M A, Corazza M, Patrizi A, Bardazzi F. Biological therapy in psoriatic patients wishing fatherhood: a multi-centre italian experience in real life. *J Eur Acad Dermatol Venereol.* ePub 2020 mar 17 PubMedID: 32181535 | DOI: 10.1111/jdv.16376 | IFg: 6,166 | Linea 4: Infiammazione e autoimmunità
18. Goldust M, Weinberg JM, Kircik LH, Sonthalia S, Di Lernia V, Rathod D. Pityriasis Lichenoides Chronica in a Patient With Ankylosing Spondylitis Treated With Etanercept. *J Drugs Dermatol.* 2020;19(3):324-325
PubMedID: 32550684 | IFg: 2,114 | Linea 4: Infiammazione e autoimmunità
19. Di Lernia V, Bianchi L, Guerriero C, Stingeni L, Gisondi P, Filoni A, Guarneri C, Belloni Fortina A, Lasagni C, Simonetti O, Neri I, Zangrilli A, Moretta G, Hansel K, Casanova D, Girolomoni G, Cannavò SP, Bonamonte D. Adalimumab in severe plaque psoriasis of childhood: A multi-center, retrospective real-life study up to 52 weeks observation. *Dermatol Ther.* 2019;32(6):e13091.ePub 2019 ott 03
PubMedID: 31579972 | DOI: 10.1111/dth.13091 | IFg: 2,327
20. Odorici G, Di Lernia V, Bardazzi F, Magnano M, Di Nuzzo S, Cortelazzi C, Lasagni C, Bigi L, Corazza M, Pellacani G, Conti A. Psoriasis and pregnancy outcomes in biological therapies: a real-life, multi-centre experience. *J Eur Acad Dermatol Venereol.* 2019;33(10):e374-e377.ePub 2019 mag 27
PubMedID: 31077634 | DOI: 10.1111/jdv.15671 | IFg: 5,248
21. Di Lernia Vito, Casanova Dahiana M, Garlassi Elisa. Secukinumab in an HIV-positive patient with psoriasis. *J Dtsch Dermatol Ges.* 2019;17(6):646-648.
PubMedID: 31099169 | DOI: 10.1111/ddg.13851 | IFg: 3,664 |
22. Dehpouri T, Rokni Ghasem R, Narenjbon Nematollah A, Goldust M, Yamauchi PS, Wollina U, Lotti T, Kircik L, Lernia V, Sonthalia S, Vojvodic A, Szepietowski J, Bahadoran P, Errichetti E, Cantisani C, Atzori L, Rezaee E, Kutlubay Z, Engin B, Nisticò S, Damiani G, Conic Rosalynn R Z, Goren A, Cabrijan L, Tchernev G. Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study. *Dermatol Reports.* 2019;11(1):7965. PubMedID: 31210916 | DOI: 10.4081/dr.2019.7965
23. Di Lernia V, Goldust M. An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly. *Expert Opin Biol Ther.* 2018;18(8):897-903.
PubMedID: 30032682 | DOI: 10.1080/14712598.2018.1504016 | IFg: 3,585 |
24. Virgili A, Borghi A, Cazzaniga S, Di Landro A, Naldi L, Minghetti S, Fierro MT, Verrone A, Caproni M, Micali G, Gaspari V, Papini M, Di Lernia V, Germi L, Girolomoni G, Belloni Fortina A, Cannavò SP, Bilenchi R, Corazza M, GLS Italian Study Group. Gender differences in genital lichen sclerosus. *G Ital Dermatol Venereol.* ePub 2018 gen 24
PubMedID: 29368855 | DOI: 10.23736/S0392-0488.17.05819-9 | IFg: 0,967

31/01/2022